The Pharmacy and Poisons Board (PPB) has entered into a significant commitment with the US Food and Drug Administration (FDA) aimed at strengthening regulatory frameworks and enhancing public health protection in Kenya. This commitment, formalized through a signed statement, outlines mutual goals to bolster existing structures, explore new opportunities for collaboration, and build capacity in regulatory practices.
The collaboration between PPB and FDA aims to leverage expertise and resources to improve pharmaceutical safety, efficacy, and quality standards. By fostering closer ties, both regulatory bodies seek to advance regulatory harmonization, facilitate knowledge exchange, and promote best practices in drug regulation and public health.
The partnership is expected to contribute to enhancing the oversight of pharmaceutical products in Kenya, ensuring that medicines and medical products meet international standards and are safe for public consumption. This initiative underscores PPB’s commitment to advancing healthcare quality and regulatory excellence in collaboration with global partners like the FDA.
